Jivadco (trastuzumab duocarmazine)
- Region
- 🇪🇺 EU
- Active substance
- trastuzumab duocarmazine
- Company
- medac Gesellschaft für klinische Spezialpräparate mbH
- Status
- Application withdrawn
- Application
- EMEA/H/C/005654
- Official record
- www.ema.europa.eu
Indication
treatment of HER2 (Human Epidermal Growth Factor Receptor 2)-positive metastatic breast cancer
Regulatory milestones
No milestones recorded in the last year.
Follow Jivadco
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.